IMMUNPROTEASOMINHIBITOREN

Patent europeic · EP3710458 · En vigur

Inscripziun en il register

Numer da publicaziun
EP3710458
Numer da la dumonda
EP18822543
Gener
Patent europeic cun effect per la Svizra ed il Liechtenstein
Status
En vigur
Scrittira da patent
Concedì
Annunzià
14-11-2018
Publitgà
23-09-2020
Concedì
25-03-2026
La protecziun finescha il pli tard
13-11-2038
Proxima taxa annuala scadenta
30-11-2026
Classas IPC
C07F 5/02 (2006.01)
Prioritad
US 201762587376 P 16.11.2017
Dumonda PCT
PCT/US2018/061140 14.11.2018
Publicaziun PCT
WO2019/099582 23.05.2019
Lingua da l’annunzia
englais
Funtauna
Swissreg

Istorgia

Quai che l’Institut federal da la proprietad intellectuala ha publitgà davart quest titel, il pli nov l’emprim.

  1. 28-04-2026

    Represchentant inscrit

    Representative
    M.ZARDI & CO SA, Via Giovan Battista Pioda 6, 6900 Lugano

    Published in Swissreg on 28.04.2026

  2. 25-03-2026

    Concedì

    Specification status
    Non-published patent application → Granted patent
    Status of protective title
    Initiated → Active

    Published in Swissreg on 25.03.2026

Partidas

Possessur

Principia Biopharma Inc.

220 East Grand Avenue, South San Francisco, CA 94080, US

Represchentant

M. ZARDI & CO SA

M.ZARDI & CO SA

Via Giovan Battista Pioda 6, 6900 Lugano

Inventur

LOU, Yan

South San Francisco California 94080, US

OWENS, Timothy Duncan

South San Francisco California 94080, US

BRAMELD, Kenneth Albert

South San Francisco California 94080, US

GOLDSTEIN, David Michael

South San Francisco California 94080, US

Il register numna mintga partida cun num ed adressa. In possessur u in represchentant vegn collià cun in’organisaziun, sch’exact ina unitad giuridica dal register da commerzi porta ses num; la via d’ina partida betg enconuschida uschia na vegn betg mussada qua.